Californian biotech firm Amgen (Nasdaq: AMGN) now has full marketing approval in the USA for Blincyto (blinatumomab) in a particular kind of acute lymphoblastic leukemia.
Green-lighting the company’s supplemental Biologics License Application, the US Food and Drug Administration upgraded its accelerated approval status based on data from the Phase III TOWER and Phase II ALCANTARA studies, adding data on overall survival rates to the label.
After bullish overnight trading, shares in the company opened nearly 1% higher in New York today, and continued to rise through the morning.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze